The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics
The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics
The 10th International Electronic Conference on Medicinal Chemistry & The 2nd Electronic Conference on Pharmaceutics
Part of the International Electronic Conference on Pharmaceutics series
Part of the International Electronic Conference on Medicinal Chemistry series
Event's Timezone: Central European Time
21 September 2025
5 October 2025
31 October 2025
Pharmacokinetics, Pharmacodynamics, Drug Candidates, Radiopharmaceutical Sciences, Biomolecules
Welcome from the Chairs
This platform seeks to provide a forum for discussion for scientists from around the world to share recent developments and innovative ideas in medicinal chemistry and pharmaceutics. This will allow students, researchers, and experts to share their latest theories, results, models, and applications within this multidisciplinary area of knowledge. This is an entirely online conference that will be held in November at https://sciforum.net/event/ECMC-P2025. No registration fee will be charged to participants, and an added advantage is the lack of cost for flights, hotels, etc.
• Biomolecules, natural products, phages, and cells as therapeutic tools
• Biological targets and biomarkers
• Radiopharmaceutical sciences, radiochemistry, (hybrid) imaging, and nuclear medicine
• Nanotechnology
• Pharmacokinetics and pharmacodynamics
• Pharmaceutical preparations and drug delivery
Researchers are invited to provide a short abstract (250 words maximum without figures and references) online, through this link from now until 21 September 2025.
Event Chairs
1. Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), Porto, Portugal
2. Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, Porto, Portugal
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain
Scientific Committee Members
Dr. Stefano D’Errico graduated in Chemistry in 2004 from the University of Naples Federico II, presenting an experimental thesis in organic chemistry titled “Synthesis of L-Iminosugars, Potential Glycosidase Inhibitors.” He earned his Ph.D. in Biotechnology Sciences in 2009, defending a thesis titled “Synthesis and Structural Characterization of Quadruplex-Forming Oligonucleotides and Studies on Solid-Phase Synthesis of Nucleoside and Nucleotide Analogues.” Since 2022, he has been working as tenure-track researcher at the Department of Pharmacy, University of Naples Federico II. During his doctoral and postdoctoral studies, Dr. D’Errico focused on developing innovative synthetic strategies for the preparation of small molecules inspired by marine natural products. Additionally, he specialized in the synthesis of modified nucleosides and nucleotides, as well as the solid-phase synthesis of oligonucleotides, with applications in medicinal and supramolecular chemistry. His scientific profile is demonstrated by 80 papers published in peer-reviewed international journals and participation in research projects funded by European and national grants. Additionally, he has been speaker at numerous schools and conferences on organic synthesis and is member of the editorial boards of several peer-reviewed scientific journals.
Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
Daniela De Vita is an Associate Professor at the Department of Environmental Biology at Sapienza University of Rome. She earned her Master’s degree in Pharmaceutical Chemistry and Technology from Sapienza in 2004 and has been working ever since pursued research in the fields of phytochemistry and pharmaceutical chemistry. Her work focuses on the study of natural compounds and their potential therapeutic applications, with particular interest in plant-derived substances and their biological activities. Professor De Vita has published extensively in international scientific journals and actively participates in multidisciplinary research projects exploring the relationship between plant chemistry and human health.
Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
M. Matilde Marques was born in Santarém, Portugal. She holds B.S. and Ph.D. degrees in Chemical Engineering and a Habilitation title (D.Sc.) in Chemistry from Instituto Superior Técnico (IST), University of Lisbon, Portugal. She conducted postdoctoral work in Chemical Carcinogenesis at the FDA National Center for Toxicological Research, USA, and is currently a full professor of Organic and Medicinal Chemistry at IST, where she has coordinated the M.Sc. and Ph.D. Chemistry Programs and held multiple institutional positions. She recently served as vice-chair of IST’s Scientific Council (2017-2024). Her research focuses on the molecular mechanisms of toxicity induced by environmental (e.g.,aromatic amines, acrylamide) and therapeutic (e.g., antiestrogens, anti-HIV drugs) xenobiotics, on the development/validation of analytical methodologies for the detection and quantitation of biomarkers of exposure to toxic agents, and on the design, synthesis, and biological evaluation of potential therapeutic agents. She has served as Chair of the Division of Medicinal Chemistry of the Portuguese Chemical Society and Council Member of the European Federation for Medicinal Chemistry (2016-2020). She serves on the Editorial Board for Pharmaceuticals, has served several terms on the Editorial Advisory Board for Chemical Research in Toxicology, and has served as team-member, subgroup chair, and overall chair on multiple working groups for WHO’s International Agency for Research on Cancer.
Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, USA
Dr. Guangshun Wang is a Professor in the Department of Pathology, Microbiology, and Immunology at the University of Nebraska Medical Center (UNMC), Omaha, Nebraska, USA. His research focuses on host defense antimicrobial peptides (AMPs) and their potential applications. Dr. Wang has contributed to the antimicrobial peptide field by constructing the original antimicrobial peptide database (APD; https://aps.unmc.edu), determining three-dimensional structures of AMPs such as human cathelicidin LL-37, and designing novel antimicrobial peptides to eliminate drug-resistant pathogens and biofilms. Dr. Wang has published over 140 original articles, reviews, and book chapters with seven US patents awarded. Dr. Wang has edited books, organized conferences, attended peptide-round tables, served as research oversight committee, and national and international grant reviewer.
Center of Health Sciences, Laboratory of Molecular Modeling and Computational Structural Biology, Federal University of Rio de Janeiro, IPPN, Rio de Janeiro, Brazil
Professor of Computational Biophysical Chemistry at the Walter Mors Natural Products Research Institute, Health Sciences Center of the Federal University of Rio de Janeiro, Brazil. B.A in Industrial Chemistry (1992); postgraduate degree (lato sensu) in Economic Engineering and Industrial Management from the Polytechnic School of the Federal University of Rio de Janeiro, Brazil (1995); M.Sc. and a Ph.D. in Computational Chemistry from the Military Institute of Engineering, where I did research with J. Daniel Figueroa-Villar, Brazil, and Anton J. Hopfinger, USA (2000). Before assuming my (tenured) position as a university professor, I worked as: chemist in Brazilian chemical, and aviation and aerospace component manufacturing companies; postdoctoral scientist at the Institute of Chemistry of the Federal University of Rio de Janeiro, Brazil; Research Specialist at The Chem21, Inc., USA; senior postdoctoral scientist at the University of Illinois at Chicago College of Pharmacy, USA; Research Associate at University of British Columbia Department of Medicine, Canada; senior scientist at the Institute of Drug Technology (Farmanguinhos)/Fiocruz; and visiting scientist at the Inflammation Laboratory of IOC/Fiocruz, Brazil. My main scientific interests are: Medicinal Chemistry; Structural Biology; Immunology; Virology; Organic Reaction Mechanisms; and Enzyme Catalysis.
Department of Pharmacognosy, Faculty of Pharmacy, Lokman Hekim University, Ankara, Türkiye
Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
Alessandra Ammazzalorso is an Associate Professor in Medicinal Chemistry at the Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara (Italy). She obtained her degree in Pharmaceutical Chemistry and Technology and Ph.D. in Pharmaceutical Sciences from the same University. Her research work is focused on the synthesis of novel compounds targeting Peroxisome Proliferator-Activated Receptors, with a special attention to the antitumor activity of their agonists and antagonists. She is also involved in the identification of enzyme inhibitors as anticancer agents. Her research activity is documented by papers in international peer reviewed journals, contributions to scientific meetings, and participation in international and national research projects. She is also a reviewer for several high-ranked medicinal chemistry journals, and she serves as an editorial board member and guest editor for international journals.
Department of Agriculture and Forestry, University of Warmia and Mazury, Olsztyn, Poland
UCIBIO/REQUIMTE, MedTech-Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal
School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
Mary J. Meegan completed her PhD degree in University College Dublin under the direction of Professor Dervilla Donnelly in the area of natural product chemistry and subsequently carried out postdoctoral research at the University Chemical Laboratory, Cambridge University in the research group of Professor Alan Battersby in the area of porphyrin synthesis and biosynthesis. Following further research periods at University College Dubin and CNRS Gif-sur-Yvette, she was appointed as lecturer in Pharmaceutical Chemistry at the School of Pharmacy and Pharmaceutical Sciences in Trinity College Dublin. She has research experience in the general area of pharmaceutical and medicinal chemistry, and has published extensively in international scientific journals covering topics such as design and synthesis of anticancer drugs, drug impurity profiling, synthetic methods for library design and in vitro screening. She has extensive experience in scientific and technical management having led an active research group, has acted as Head of the Department of Pharmaceutical Chemistry and as subject area head of Pharmaceutical Chemistry at the School of Pharmacy.
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy
ACADEMIC POSITIONS Associate professor (Medicinal chemistry, Drug design and development) – School of Pharmacy and Department of Biomolecular Sciences at the University of Urbino Carlo Bo (March 2015 - today). Assistant professor (medicinal chemistry field) – School of Pharmacy and Department of Biomolecular Sciences at the University of Urbino Carlo Bo (November 1997 - February 2015). Assistant professor (medicinal chemistry field) – Faculty of Pharmacy and Department of Pharmaceutical Sciences at the University of Chieti “G. D’Annunzio” (AY 1996-1997). UNIVERSITY STUDIES PhD in Medicinal chemistry – Drug-chemical Department at the University of Bari Master Degree in Pharmacy – Faculty of Pharmacy at the University of Urbino RESEARCH FIELDS Design, synthesis, structure-activity relationships and pharmacological activity of molecules belonging to various classes of drugs, mainly those interacting with the endocannabinoid system and fatty acid ethanolamides (CB ligands, FAAH, MGL and NAAA inhibitors), anticancer and antiviral drugs, and antibiofilm surfactants. The results, based on collaborations with international and national scientific groups, led also to both international patents and clinical trials in the field of endocannabinoid enzyme inhibitors. Published papers and patents are available on the web page https://scholar.google.com/citations?user=LGrccH8AAAAJ&hl=en. INTERESTS: medicinal chemistry; drug design; cannabinoids; sugar-based surfactants REFEREE ACTIVITY A various number of articles in international journals, such as Archiv der Pharmazie, Bioorganic & Medicinal Chemistry, Biochimie, ChemMedChem, Current Drug Targets, Current Topics in Medicinal Chemistry, Drugs and Drug Candidates, European Journal of Medicinal Chemistry, Food chemistry, International Journal of Molecular Sciences, Journal of Medicinal Chemistry, Marine Drugs, Molecules and Pharmaceuticals have been referenced.
Institute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, Universität Münster, Münster, Germany
Department of Chemistry, University of Florence, Sesto Fiorentino, Florence, Italy
Prof. Maria Camilla Bergonzi is Associate professor at the School of Human Health Sciences of the University of Florence, Italy. She is titular of Course of Pharmaceutical Technology and Legislation for ungraduated students of degree course in Pharmacy and co-titular of the course Soft Matter Materials Applied to Drug Delivery Systems, Food Supplements and Cosmetic Sciences, for the master degree in Advanced Molecular Sciences. She is author of over 130 original papers in international peer-reviewed journals one patent and three chapters of books (H-index 42). She has a deep background in the pharmaceutical technology and analysis of herbal drugs and herbal drug preparations. Her research includes the improvement of bioavailability and technological features of natural compounds, extracts and drugs, by using conventional and innovative micro and nanocarriers. Her studies are concerning the preparation of formulations able to cross the blood-brain barrier and to promote the oral and skin absorption. She is Editor in Chief of Drug Delivery Letters, member of Editorial Board of Pharmaceutics, Molecules, Current Drug Delivey, ChemMedChem, and Editor of several Special Issues on Drug Delivery Systems.
Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy
Giovanna Rassu is an Associate Professor at the Department of Medicine, Surgery and Pharmacy of the University of Sassari, where she conducts her research and teaching activities in the field of drug delivery. Her research primarily focuses on the design, preparation, and in-vitro, ex-vivo, and in-vivo characterization of novel drug delivery systems for various administration routes (nasal, oral, and cutaneous) to treat diseases such as cancer and neurodegenerative disorders. She is particularly involved in developing micro- and nanoparticles for nose-to-brain drug delivery, collaborating with multiple national and international research groups. To date, she has (co)authored 89 scientific publications (h-index 33) and over 100 congress communications/proceedings. Additionally, she is the inventor of a patent titled "Permeation Cells" (number: 102017000089514; European extension application PCT/IB2018/055726), which is suitable for permeation studies of substances through membranes or tissues.
Gareth received a MChem (Hons) degree from the University of Oxford in 2002. He remained in Oxford for a DPhil (PhD), supervised by Prof Dermot O’Hare, which was completed in 2005. Gareth’s PhD work was focused on the use of synchrotron techniques to monitor intercalation reactions in situ. After graduation, he worked as a post-doctoral researcher and in science program management. In September 2010 he joined London Metropolitan University as a Senior Lecturer in Pharmaceutical Science, and in November 2012 was appointed to the UCL School of Pharmacy as a Lecturer in Pharmaceutics. He was promoted to Associate Professor in 2016 and to full Professor in 2020, when he also became Head of Pharmaceutics. Gareth leads a group of around 15 researchers applying inorganic and polymer-based nanomaterials to overcome drug delivery challenges. Key areas of interest include the use of synchrotron techniques (still!) and developing theranostic systems – and the latter forms the theme of this presentation
Department of Chemistry, University of Florence, Florence, Italy
FP-BHS—Biomedical and Health Sciences Research Unit, FP-I3ID—Instituto de Investigação, Inovação e Desenvolvimento, Faculty of Health Science, Fernando Pessoa University, Porto, Portugal,
UCIBIO—Applied Molecular Biosciences Unit, MedTech—Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Porto, Portugal
Assistant Professor of Pharmaceutical Technology in the Faculty of Health Sciences at University Fernando Pessoa (Porto, Portugal) and researcher at the CEBIMED/FP-ENAS (UFP, Portugal). Graduated in Pharmaceutical Sciences (2002) and PhD in Pharmaceutical Technology from the Faculty of Pharmacy, University of Porto (2006). Currently research interests: I. Controlled delivery of drugs across biological barriers II. Design, characterization and evaluation of colloidal carriers for different applications (pharmaceutical,biotechnology, cosmetic). Editor of two academic books. Author or co-author of various papers in international scientific periodicals and of various book chapters. Reviewer for several national and international journals related to the field of Pharmaceutical Technology; Nanotechnology and Biotechnology. Co-adviser and adviser of PhD and master thesis and several graduation thesis. https://www.cienciavitae.pt//901D-160C-633E
Faculty of Pharmacy, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece
Kyriakos Kachrimanis is a Professor in Pharmaceutics, currently employed at the Laboratory of Pharmaceutical Technology of the School of Pharmacy of the Aristotle University of Thessaloniki. He received his degree in Pharmacy in 1992, and a doctorate degree in 1998, both from the School of Pharmacy of the Aristotle University of Thessaloniki. In 2001 he was appointed to the School of Pharmacy as a Lecturer in Pharmaceutics. He was promoted to Assistant Professor in 2007, to Associate Professor in 2015, and to Full Professor in 2020. He served as deputy Chair of the School of Pharmacy from 2017 to 2020, and he has been Chair of the School since 2020. His research interests include the study of solid-state properties of pharmaceuticals with focus on the solubility/dissolution enhancement of poorly soluble substances by means of crystal and particle engineering employing environmentally friendly mechanochemical processes and computational simulations.
Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy
Department of Pharmaceutical Technology, Faculty of Pharmacy, Universidad de Santiago de Compostela, Santiago de Compostela, Spain
Francisco Javier Otero Espinar is a Full Professor at the Department of Pharmacology, Pharmacy, and Pharmaceutical Technology at the University of Santiago de Compostela (USC), Spain. He earned his PhD in Pharmacy in 1990, with a dissertation on cyclodextrin-based systems to enhance drug solubility and bioavailability. His scientific work focuses on the development of innovative drug delivery systems, including mucoadhesive formulations, cyclodextrin complexes, and polymeric and lipidic nanoparticles. He has also made significant contributions to pharmacokinetics through the application of advanced imaging techniques for in vivo drug tracking and release analysis. Professor Otero Espinar has led numerous collaborative R&D projects across the pharmaceutical, veterinary, and agrochemical sectors, promoting translational research and industrial innovation. He is a member of a multidisciplinary research group dedicated to drug delivery systems. He has served as President of the Spanish Society of Industrial and Galenic Pharmacy (SEFIG) and was Dean of the Faculty of Pharmacy at USC. In addition to his academic and institutional roles, he is Section Editor-in-Chief for Drug Delivery and Controlled Release in Pharmaceutics and Associate Editor of the Journal of Drug Delivery Science and Technology. He has published extensively on cyclodextrin in drug delivery, nanoparticle-based drug carriers, ophthalmic drug delivery and integrated pharmacokinetic-imaging methodologies.
Pharmacy department, Health Faculty, Univ. Rouen Normandie, Institut CARMeN UMR CNRS 6064, Rouen, France
Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
Univ.-Prof. Dr. Klaus Kopka (HZDR, Germany) is a radiopharmaceutical chemist and holds a full professorship (W3) for Bioinorganic and Radiopharmaceutical Chemistry at Technical University Dresden, Germany, which is combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR] [https://www.hzdr.de/db/Cms?pNid=130]. Between 2013 and 2019 he held a W3 position at Ruprecht-Karls-University of Heidelberg, Germany. At the same time he was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center [DKFZ] in Heidelberg. In 2018 Klaus Kopka was honoured together with his colleagues Michael Eisenhut, Matthias Eder and Uwe Haberkorn with the highly recognized “The Stifterverband Science Award – Erwin Schrödinger Prize” of the Helmholtz Association. He was involved in the development of the theranostic prostate-specific membrane antigen (PSMA)-targeting radiotracers, i.e. PSMA-617 (approved as Pluvicto), PSMA-914 and PSMA-1007 (approved as Radelumin). His current research interests focus on radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide production and radionuclide theranostics; targeted endoradiotherapy; noninvasive molecular imaging. His scientific output includes 279 publications, corresponding to 14,322 citations (h-index 58) (Scopus, 11-April-2025).
Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain
Prof. Dr. Diego Muñoz-Torrero graduated in pharmacy at the University of Barcelona (1989), where he received a PhD degree (Medicinal Chemistry) in 1994. From January 1996 to December 1997, he was a postdoctoral researcher at the Institut für Organische Chemie of the Georg-August Universität (Göttingen, Germany). In 2001 he was appointed associate professor of organic and medicinal chemistry at the Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona (UB), and since July 2022 he has been full professor at the same department. He was Vice Dean of Research at the Faculty of Pharmacy and Food Sciences (UB) from November 2009 until March 2018. He is currently head of the Laboratory of Medicinal Chemistry of his faculty and member of the Governing Board of the Institute of Biomedicine of the UB (IBUB) since its founding in 2007. He is a member of the Spanish Society of Medicinal Chemistry (SEQT) and the Spanish Royal Society of Chemistry (RSEQ), Organic Chemistry Division. He currently serves as the Editor-in-Chief of the Medicinal Chemistry Section of the MDPI journal Molecules and belongs to the editorial advisory board of several medicinal chemistry journals.
Dipartimento di Scienze Chimiche e Geologiche, Università di Cagliari, Cittadella Universitaria, Monserrato, Italy
School of Pharmaceutical Sciences, Wuhan University, Wuhan, China
Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, USA
Gill Diamond received his BA in Biochemistry from the University of Pennsylvania, and his PhD in Genetics from the Hebrew University of Jerusalem. He then returned to Philadelphia to do postdoctoral research at the Children’s Hospital of Philadelphia, where he began to work on antimicrobial peptides, discovering the first beta-defensin. He was a faculty member at the University of Medicine and Dentistry of New Jersey (now part of Rutgers University) from 1993-2013, and the University of Florida from 2013-2019. Since then, he have been a professor in the Department of Oral Immunology and Infectious Diseases at the University of Louisville School of Dentistry, where he studies innate immunity of mucosal epithelium, and the development of novel antimicrobial agents based on antimicrobial peptides.
Physiology, Department of Biochemistry and Physiology, Universitat de Barcelona, Barcelona, Spain
Associate Professor at the Section of Physiology (Biochemistry and Physiology Dept., Faculty of Pharmacy and Food Sciences, UB). Her research interest focused on preclinical toxicology including nanotoxicology and extract bioactive characterization emphasizing the application of 3Rs concept. Member of the Cellular responses to xenobiotics leaded by Professor M. Pilar Vinardell, since 2001. She has participated in several national and international projects and has been the responsible of different granted projects. More than 120 published articles in indexed journals. Currently she participates in a specialization course aimed to evaluate the toxicological risk of cosmetics and in a doctoral course related to the 3Rs concept. She is vocal of the Ethics Committee for animal experimentation in Universitat de Barcelona. In summary, her expertise is mainly focused on the field of preclinical toxicology, and in the development of in vitro methods.
She is an Associate Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences at the University of Perugia (Italy). Her research activities entail selecting new druggable targets for innovative therapies, designing new chemical entities with desired biological activities, developing synthetic procedures for preparing compounds and conducting SAR studies. She has participated in several national and international projects and has led on various funded projects. Her research, documented by 80 scientific publications in peer-reviewed journals, has mainly focused on developing novel small drug-like molecules that act as antiviral agents. More recently, her work has focused on discovering antitumour agents, such as PARP, AKT1 and PolQ inhibitors, and identifying small molecules that target RNA.
Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, USA
Conor Caffrey is a Professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego. He is also the Director of the Center for Discovery and Innovation in Parasitic Diseases (CDIPD) which was founded in 2001 with the mission to advance preclinical drug discovery and development for, and education regarding, neglected tropical diseases (NTDs), which primarily affect low- and middle-income countries. Conor completed his PhD studies in molecular and biochemical parasitology at University College Dublin, Ireland in 1994, and then performed post-doctoral research at the University of Heidelberg in Germany, and the University of California San Francisco. After a brief faculty position at the University of Wales in the UK, Conor returned to UC San Francisco in 2001 to lead his own group within the newly-formed CDIPD. In 2015, Conor relocated his team to UC San Diego. In addition to NIH and international philanthropic research project support, Conor’s team and the CDIPD routinely host national and international scholars and trainees. Finally, the CDIPD offers didactic and hands-on training in drug discovery and development for a number of NTD pathogens, and is engaged in capacity-building projects with institutions in Africa and South America.
Faculty of Pharmacy and Pharmaceutical Sciences, Katz Group-Rexall Centre for Pharmacy & Health Research, University of Alberta, Edmonton, Canada
Faculty of Pharmacy & Pharmaceutical Sciences, Katz Group-Rexall Centre for Pharmacy & Health Research, University of Alberta, Edmonton, Canada
Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, China
Department of Drug Science and Technology, University of Torino, Torino, Italy
Department of Chemistry “Ugo Schiff”, University of Florence, Sesto Fiorentino, Italy
Prof. Dr. Anna Rita Bilia is full professor of pharmaceutical technology at the University of Florence. She is former Director of the Post-graduate School of Hospital Pharmacy. In 1995 she got the national award "Claudio Redaelli" for outstanding young researchers in the field of phytochemistry and in 2002 she got the international "Egon Stahl Medal" for researchers younger than 40 years, working in natural products. In 2018 she got the Qihuang International Prize from the China Association of Chinese Medicine for her outstanding achievements in the field of analysis and innovative formulations of extracts and natural products from Chinese medicine. She is leading the group of natural products analysis and pharmaceutical technology at the Department of Chemistry. She is the president of Interdepartmental Center of Services for Biotechnologies of Agrarian, Chemical, Industrial interest (CIBIACI) of University of Florence. She is expert of the European Pharmacopoeia and member of the TCM group. She is former president of the International Society for Medicinal Plant and Natural Product Research (GA). She is the Italian delegate of the board of directors, member of the scientific committee and vice chair of the European Scientific Cooperation on Phytotherapy (ESCOP). She is former president of the Italian Society of Phytochemistry and Sciences of Plants for Medicinal, Food and Cosmetic use (SIF). Prof. Bilia’s list of publications shows more than 280 papers in the most reputed international journals of her field of research, she is authors of numerous invited book monographs and chapters.
Sessions
S2. Invited lectures
S3. General
S4. New Small molecules as drug candidates
S5. Natural Products and Biopharmaceuticals
S6. Novel and Sustainable approaches in Medicinal Chemistry
S7. Emerging technologies in drug discovery
S8. Radiopharmaceuticals
S9. Drug disposition and drug formulation
S10. Nanomedicine and Nanotechnology
S11. Formulation, Drug Delivery and Controlled Release
S12. Biopharmaceutics, Pharmacokinetics and Pharmacodynamics
Registration
The registration for ECMC-P 2025 will be free of charge! The registration includes attendance to all conference sessions.
If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.
Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 31 October 2025.
Instructions for Authors
- Scholars interested in participating in the conference can submit their abstract (250 words maximum without figures and without references) online at this website until 21 September 2025.
- Based on the submitted abstract, the conference committee will conduct a pre-evaluation of whether a contribution from the authors of the abstract will be welcome for The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics. All authors will be notified by 5 October 2025 with regard to the acceptance status of their abstract.
- If the abstract is accepted for this conference, the author will be invited to prepare a full description of their work in the form of a poster, slideshow, or video at their best convenience, until the submission deadline of 12 October 2025.
- Posters must be uploaded as a PDF file using the Poster template file available at the end of this section.
- Slideshows must be uploaded as a PDF file using the PPT template file available at the end of this section.
- Flash communications (5 minutes) and communications (10-20 minutes) must be uploaded as an mp4/.webm/.ogg (max size: 250Mb) file (video) using the PPT template file available at the end of this section.
- Tips for authors: if you would like to prepare a video based on your PowerPoint presentation, you may use the "record slide" function in PowerPoint.
The presentation for accepted submission should be uploaded before 12 October 2025 via submission dashboard, for a final check and approval. Each work will be directed to the appropriate panel (posters, slideshows, flash communications, communications) by the conference organizing team.
- Length of the presentation: no more than 30 slides
- The slides should be in PDF format.
- Slide 1 (strictly one slide): Title, authors’ names, affiliation(s), email address of corresponding author, logos of the laboratory and/or institution (not mandatory).
- Slide 2 (strictly one slide): Graphical abstract; repeat the title of the presentation but avoid other text as far as possible.
- Slide 3 (strictly one slide): Abstract (max. 250 words) and 3–5 keywords, separated by semicolons.
- Slide 4 and following slides: These should contain (in the given sequence) Introduction, Results and Discussion, Conclusions.
- Last slide: Acknowledgments, and logos of sponsors (not mandatory).
- ECMC-P 2025 Slides Template should be used.
Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and comment about the posters. Posters can be presented without an accompanying proceedings paper. However, they will not be added to the proceedings of the conference.
- The poster should be in PDF format.
- The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
- The content of the poster should be a comprehensive presentation of your accepted submission.
- No copyright issues with any elements in the poster
- ECMC-P 2025 Poster Template should be used.
Flash communications (3-5 minutes) and communications (15 minutes maximum) must be uploaded as an mp4/.webm/.ogg (max size: 250Mb) file (video) using the PPT template file available at the end of this section.
- Communication (15 minutes maximum).
- Flash Communications (3-5 minutes).
After the event, the participants of ECMC-P 2025 will be able to download an electronic Certificate of Attendance by logging in to your Sciforum personal account. Once you are logged-in, go to your profile and click on 'My certificates'. A list of all Sciforum events you have attended is available and you simply have to click on "Download" next to the correct event.
It is the author's responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunities
All participants will be invited to submit a full paper describing their work. The papers will be peer-reviewed and, upon acceptance, published in a Special Issue covering the event using templates provided by the conference. A 20% discount on the article processing charge will be applied.
Event Awards
The open-access, peer-reviewed journals Pharmaceuticals and Pharmaceutics will present awards totaling 1600 CHF for the Best Poster, Best Slideshow, Best Flash Communication, and Best Communication, as well as 500 CHF for the Best Invited Lecture. Additionally, one participant will be granted the opportunity to engage in a One-Day Microwave Practice/Test. All submissions will be evaluated independently of their respective sessions. Members of the Scientific Committee will be responsible for selecting the winning entries based on predefined criteria.
The Awards
Number of Awards Available: 4
The open-access peer-reviewed journals Pharmaceuticals and Pharmaceutics will provide a prize of 400 CHF for each award.
Number of Awards Available: 1
The open-access peer-reviewed journals Pharmaceuticals and Pharmaceutics will offer a 500 CHF award to the participant with the Best Invited Lecture Award.
Number of Awards Available: 1
One Day Microwave Practice/Test for free offered by Microwave Technologies Consulting. Selection will be made by the Company following strict scientific criteria.
Sponsors and Partners
Organizers
Media Partners
Conference Secretariat
Ms. Gill Tan
Ms. Adelina Platon
Email: ecmc-p@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
